CAPRIE


Also found in: Acronyms, Wikipedia.
Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events. A trial comparing an antiplatelet agent, clopidogrel, to aspirin in decreasing the risk of stroke, infarction, or vascular death in patients with evidence of vascular disease
Conclusion Long-term clopidogrel is more effective than aspirin in decreasing composite end-points for patients with symptomatic ASHD; clopidogrel’s safety is comparable to medium dose aspirin

CAPRIE

Cardiology A clinical trial–Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events which compared the efficacy of the antiplatelet agent, clopidogrel, with aspirin therapy as a stroke prophylaxis. See Clopidogrel.
References in periodicals archive ?
The subjects in the CAPRIE trial were either survivors of a nondisabling stroke or MI or had manifestations of PAD with IC or a limb revascularization.
However, Prasugrel has to go through an intensive Phase III clinical program to translate the better platelet inhibition seen in Phase I studies to improved clinical outcomes in terms of reducing MI and other CAD instances and death compared to Clopidogrel - essentially an expensive and time consuming study similar to CAPRIE study done for establishing Clopidogrel's marginal superiority over Aspirin.
The CAPRIE (1996) study showed that PLAVIX(R) (Clopidogrel) and Aspirin are quite toxic with over 50% of those who take either of them suffer from various toxic side effects.
The CAPRIE (1996) study showed that the largest selling antiplatelet drugs PLAVIX(R) (Clopidogrel) and Aspirin are quite toxic with over 50% of those who take either of them suffer from various toxic side effects.